Double-blind, Placebo-controlled, Randomized, Ascending Single Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LGD-6972 in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus
Latest Information Update: 07 Nov 2021
At a glance
- Drugs RVT-1502 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; First in man
- Sponsors Ligand Pharmaceuticals
- 12 Sep 2016 According to Ligand Pharmaceuticals Median Release results of two phase I stuidies (phase Ia and phase Ib) were published in the Journal of Diabetes, Obesity and Metabolism.
- 15 Aug 2016 Results published in the Ligand Pharmaceuticals Media Release
- 08 Mar 2015 Results presented at The 97th Annual Meeting of the Endocrine Society.